DEGARELIX ROLE AND PLACE IN THE COMBINED TREATMENT OF PATIENTS WITH PROSTATE CANCER IN COMBINATION WITH CONCURRENT RADIOTHERAPY
Abstract
Application Degarelix ADT patients who underwent combined radiotherapy, already on the first results showed the high efficiency and low toxicity. For patients with localized prostate cancer with intermediate factors and a poor prognosis, as well as for patients with locally advanced disease, we recommend a hormone antagonists of gonadotropin-releasing hormone (GnRH) Firmagon (Degarelix) not only during concomitant radiation therapy, but also as neoadjuvant and adjuvant treatment.
About the Authors
A. Y. Pavlov
Russian Scientific Center of Roentgenoradiology of Russian Health Ministry
Russian Federation
Russian Federation
R. A. Gafanov
Russian Scientific Center of Roentgenoradiology of Russian Health Ministry
Russian Federation
Russian Federation
S. V. Fastovets
Russian Scientific Center of Roentgenoradiology of Russian Health Ministry
Russian Federation
Russian Federation
A. D. Tsybulsky
Russian Scientific Center of Roentgenoradiology of Russian Health Ministry
Russian Federation
Russian Federation
T. K. Isaev
Russian Scientific Center of Roentgenoradiology of Russian Health Ministry
Russian Federation
Russian Federation
References
1. Давыдов М.И., Матвеев В.Б.//Вестник РОНЦ им. Н.Н. Блохина. 2011. Т. 22, № 3 (85). Прил. 1. С. 13-14
2. Оськина Н.А., Ермоленко Н.А., Боярских У.А. и др. Изучение ассоциации однонуклеотидных полиморфных замен в генах ферментов антиоксидантной системы с риском развития рака предстательной железы в Сибирском регионе России//Сибирский онкологический журнал. 2013. № 3(57). С. 37-42
3. Чиссов В.И., Алексеев Б.Я., Русаков И.Г. Онкоурология: национальное руководство. М.: ГЭОТАР-Медиа, 2012. С. 227-250
4. Anderson J. Treatment of Prostate Cancer -The Role of Primary Hormonal Therapy//EAU Update Series. 2003. № 1. P. 32-39
5. Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer//Lancet. 2002. Vol. 360. P. 103-108
6. Ferlay J., Shin H.R., Bray F. et al. GLOBOCAN, Cancer Incidence and Mortality Worldwide: IARC Cancer Base. 2008. № 10
7. Hanks G.E., Lu J.D., Machtay M. et al. RTOG 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate//Proc. Am. Soc. Clin. Oncol. 2000. Vol. 19. A. 327
8. Klotz L., Boccon-Gibod L., Shore N.D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer//BJU Int. 2008. Vol. 102. P. 1531-1538
9. Princivalle M., Broqua P., White R. et al. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist//J. Pharmacol. Exp. Ther. 2007. Vol. 320. P. 1113-1118
10. PR Newswire. FDA approves Ferring Pharmaceuticals’ Degarelix (generic name) for the treatment of advanced prostate cancer. PR Newswire, Europe Ltd., 2008
11. Pilepich M.V., Winter K., Roach M. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation before and during radiothrerapy in locally advanced carcinoma of the prostate//Int. J. Radiat. Oncol. Biol. Phys. 2001. Vol. 50. P. 1243-52
12. Schröder F.H., Boccon-Gibod L., Tombal B. et al. Degarelix versus leuprolide in patients with prostate cancer: effect in metastatic patients as assessed by serum alkaline phosphatase//Ann. congress EAU, 2009. Abst. 40
13. Van Poppel H., Tombal B., de la Rosette J.J. et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer//Eur. Urol. 2008. Vol. 54. P. 805-809
Review
For citations:
Pavlov A.Y., Gafanov R.A., Fastovets S.V., Tsybulsky A.D., Isaev T.K. DEGARELIX ROLE AND PLACE IN THE COMBINED TREATMENT OF PATIENTS WITH PROSTATE CANCER IN COMBINATION WITH CONCURRENT RADIOTHERAPY. Siberian journal of oncology. 2013;1(6):44-47. (In Russ.)
Views:
511
Email this article 
